Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 10/2020

01-10-2020 | ANCA-Associated Vasculitis | Letter to the Editor

Biosimilars for vasculitis: promise requires validation by quality studies

Authors: Durga Prasanna Misra, Pallavi Patro, Vikas Agarwal

Published in: Clinical Rheumatology | Issue 10/2020

Login to get access

Excerpt

We read with great interest the recent description of the effectiveness of rituximab biosimilar for induction and maintenance of remission in granulomatosis with polyangiitis (GPA) [1]. The exploration of biosimilars in the management of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) [2] and other vasculitides addresses an important knowledge gap, due to potential cost-savings and wider accessibility for biosimilars in low- and middle-income countries for the treatment of these chronic diseases. Real-world evidence often provides valuable information in this regard, complementary to higher quality evidence from randomized controlled trials [3]. …
Literature
1.
2.
3.
4.
5.
Dincses E, Esatoglu SN, Ozguler Y et al (2019) Biosimilar infliximab for Behçet’s syndrome: a case series. Clin Exp Rheumatol 37(Suppl 121):111–115PubMed
6.
7.
8.
Vacchi C, Visentini M, Gragnani L, Fraticelli P, Tavoni A, Filippini D, Saccardo F, Lauletta G, Colantuono S, Atzeni F, Pioltelli P, Manfredi A, Casato M, Zignego AL, Monti G, Pietrogrande M, Galli M, Sebastiani M (2020) Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar). Intern Emerg Med. https://​doi.​org/​10.​1007/​s11739-020-02386-0
9.
Metadata
Title
Biosimilars for vasculitis: promise requires validation by quality studies
Authors
Durga Prasanna Misra
Pallavi Patro
Vikas Agarwal
Publication date
01-10-2020
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 10/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-020-05309-8

Other articles of this Issue 10/2020

Clinical Rheumatology 10/2020 Go to the issue

Original Article

Validation and implementation of a patient-reported experience measure for patients with rheumatoid arthritis and spondyloarthritis in the Netherlands

Original Article

Enthesitis and joint erosions are disease traits associated with cardiovascular risk in psoriatic arthritis

Original Article

Comparison of the short-term results of single-dose intra-articular peptide with hyaluronic acid and platelet-rich plasma injections in knee osteoarthritis: a randomized study

Brief Report

Role of HLA-DRB1*04 in the susceptibility and HLA-DRB1*08 in the protection for development of rheumatoid arthritis in a population of Southern Mexico: brief report

Clinical Image

Diplopia and ocular pain due to orbital myositis

Editorial

The perennial search for alternatives to corticosteroids in rheumatology: is there light at the end of the tunnel?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits